In this free-to-attend, 25-minute, bite-sized webinar, hosted by DDW and supported by Revvity, Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted protein degradation (TPD) in oncology research, with a specific focus on CDK2 degradation for potential cancer treatments. Johnson will be joined during the Q&A by Rachel Mendes, Senior Director of Business Development & Strategy at Beantown Biotech.

Beantown Biotech is a contract research organisation specialising in drug discovery services with extensive expertise in assay development and screening technologies. Johnson will present the company’s successful implementation of TPD strategies. 

Attendees will learn:

• How TPD offers a novel therapeutic approach for previously undruggable targets in cancer pathways
• The critical role of CDK2 in cell cycle regulation and its significance in oncology research.
• Through a comprehensive case study, the company will demonstrate various no-wash high-throughput assay methodologies for quantifying CDK2 degradation and evaluating TPD efficacy.